IVD News and Research

RSS

BD MAX MRSA Assay receives CE Mark approval

BD Diagnostics, a segment of BD, today announced that it obtained CE Marking for the BD MAX MRSA Assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) in patients.

From BD (Becton, Dickinson and Company) 24 Nov 2011

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today.

18 Nov 2011

SurModics to sell Pharma assets to Evonik for $30 million

SurModics, Inc., a leading provider of surface modification technologies to the healthcare industry, announced today that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash.

2 Nov 2011

SFDA approves China Medical Technologies' colorectal cancer assay

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that China's State Food and Drug Administration has approved the Company's real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog assay as a companion diagnostic test for the use of a targeted drug for the treatment of colorectal cancer patients.

13 Oct 2011

NanoString introduces nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation nCounter Analysis System.

From NanoString Technologies 13 Oct 2011

Asuragen announces data from Signature LTx v2.0 clinical study on leukemia

Asuragen, Inc. announced today that data from a study evaluating its Signature LTx v2.0, a CE-marked IVD test, for the multiplex detection of fusion transcripts associated with ALL, AML and CML leukemia, will be presented at the upcoming Planet XMAP Europe being held September 28 - 29, 2011 in Vienna, Austria.

27 Sep 2011

IVAX Diagnostics net revenues decrease 0.4% to $4,375,000 for quarter ended June 30, 2011

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended June 30, 2011.

23 Aug 2011

Quanterix's ELISA precisely measures low abundance cytokines in Crohn's disease

Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.

20 Aug 2011

China Medical first fiscal quarter net revenues increase 27.4% to US$36.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 today.

16 Aug 2011

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approvals for its prostate cancer FISH detection kit and Topoisomerase 2-alpha FISH detection kit from the State Food and Drug Administration of the People's Republic of China.

10 Aug 2011

Leica Microsystems, CMED partner to co-develop and market automated FISH kits

China Medical Technologies, Inc. (CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, and Leica Biosystems, a division of Leica Microsystems, a world leader in microscopes and scientific instruments, today announced that they have established a sales, research and development collaboration to co-develop and market automated FISH kits to be used on the Leica BOND system.

8 Aug 2011

Diamedix, LABSCO sign distribution agreement for instrumentation systems and test kits

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, announced that Diamedix Corporation, IVAX Diagnostics' wholly-owned subsidiary located in Miami, Florida, has signed a three-year agreement with Laboratory Supply Company, the largest privately held supplier of diagnostic instrumentation and clinical laboratory products to hospitals, physician office laboratories, reference labs and other non-acute care settings in the United States.

4 Aug 2011

SDIX adds nine new polyclonal antibodies to IVD reagents portfolio

SDIX, a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week.

3 Aug 2011

Waters receives CE mark for MassTrak Immunosuppressants XE Kit

Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus in liver and kidney transplant patients and everolimus in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

25 Jul 2011

Roche signs agreement to acquire mtm laboratories

Ventana Medical Systems, Inc., a member of the Roche Group, announced today that Roche has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany.

From Roche Sequencing and Life Science 19 Jul 2011

Affymetrix commences shipment of gene profiling reagents

Affymetrix, Inc. today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip Instrument System, which is used by Affymetrix partners for assay development.

12 Jul 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011